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Objective: Lung transplantat ion remains limited by donor organ ischemic 
time, inadequate graft preservation, and reperfusion injury. We evaluated 
lung preservation with use of an extracellular solution, with or without the 
addit ion of blood, as compared with preservation with the intracel lular 
Euro-Coll ins solution. Methods: With use of an isolated, whole blood 
perfused/ventilated rabbit  lung model, we studied three groups of animals. 
Lungs were flushed with Euro-Collins, low-potassium dextran, or 20% 
blood-low-potassium dextran solution. Lungs were harvested en bloc, 
stored inflated at 4° C for 18 hours, and then reperfused at 60 ml/min with 
whole blood. Continuous measurements of pulmonary artery pressure, 
pulmonary vascular resistance, and dynamic airway compliance were 
obtained. Fresh, nonrecirculated venous blood was used to determine the 
single-pass pulmonary venous-arterial oxygen gradient. Results: Lungs 
preserved with Euro-Coll ins solution demonstrated elevated pulmonary 
artery pressure and pulmonary vascular resistance when compared 
with those preserved with low-potassium dextran and 20% blood-low- 
potassium dextran solutions (pulmonary artery pressure: 40.8 -- 2.2 mm 
Hg vs 28.9 -+ 2.4 mm Hg and 28.3 - 1.5 mm Hg, respectively, p < 0.001; 
pulmonary vascular resistance: 46.0 --- 3.1 x 103 dynes .sec ,  cm -s  vs 
29.0 -- 4.2 x 103 dynes • see. em -s and 28.8 - 2.3 x 103 dynes • sec. cm -5, 
respectively, p < 0 .001) .  Euro-Coll ins solution-preserved lungs demon- 
strated a significant drop in compliance when compared with those 
preserved with low-potassium dextran and 20% blood-low-potassium dex- 
tran ( -21.9% _ 4.7% vs 1.8% _ 3.3% and 1.4% -+ 6.2%, respectively; p = 
0.002). Oxygenation was improved with low-potassium dextran and 20% 
blood-low-potassium dextran solutions as compared with that with Euro- 
Collins solution (296.3  - 54.6 mm Hg and 290.2 -+ 66.4 mm Hg, 
respectively, vs 37.2 +- 4.6 mm Hg; p = 0.001). Conclusions: Extracellular 
solutions provided superior preservation of pulmonary function in this 
rabbit  lung model of ischemia-reperfusion. However, the addition of blood 
does not confer any demonstrable advantage over low-potassium dextran 
solution alone with use of an 18-hour period of cold ischemia. (J Thorac 
Cardiovasc Surg 1996;112:1515-21) 
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T he current success of clinical lung transplantation relies on limited cold ischemic periods and ade- 
quate graft preservation. Despite advances in lung 
preservation, reperfusion injury continues to be an 
unpredictable and often devastating occurrence. 
Numerous investigations have identified methods of 
preventing or ameliorating the effects of reperfusion 
injury. 1-4 However, ischemia-reperfusion injury of 
the lung continues to be in part attributable to 
inadequate graft preservation. The most commonly 
used method of lung preservation is hypothermic 
single-flush perfusion of the pulmonary vascula- 
ture. 5 This technique allows rapid cooling of the 
graft and distribution of a preservation solution 
throughout the lung. Acceptable results with single- 
flush perfusion have been attained, although the 
optimal preservation solution to accompany this 
technique remains undetermined. 
Theoretic advantages for the use of either extra- 
cellular or intracellular types of preservation solu- 
tions exist, and the controversy over which type of 
solution provides optimal protection of the lung 
continues. Low-potassium extracellular-type solu- 
tions have been used both clinically and in experi- 
mental models and demonstrate the potential for 
improved lung function and prolonged storage. 6-~2 
Other authors have also reported excellent results 
with the use of intracellular-type solutions, 1345 of 
which Euro-Collins olution is most commonly used. 
The potential benefits of blood-based preservation 
solutions have also been described) 6-1s 
We have previously reported that the use of 
extracellular-type reservation solutions in the set- 
ting of high-flow reperfusion results in improved 
lung function 19 and that the intracellular-type Euro- 
Collins solution exacerbates lung injury. 2° Given 
these findings, in the current study we hypothesized 
that extracellular-type reservation solutions would 
provide superior lung function as compared with 
results using the standard intracellular-type solu- 
tion, Euro-Collins solution, after an extended 18- 
hour period of cold ischemia. Because of its efficacy 
in cardiac protection, the potential benefit of using a 
blood-based solution was also investigated in an 
isolated blood-perfused/ventilated rabbit lung 
model. 
Material and methods 
Lung-heart block harvesting. In the following experi- 
mental model, previously described by our laboratory, I9 
23 adult New Zealand White rabbits of either sex (3.0 to 
3.5 kg) were randomized to three experimental groups. 
Each rabbit was anesthetized with intramuscular ketamine 
(50 mg/kg) and xylazine (5 mg/kg). Tracheal intubation 
was done via a tracheostomy and followed by paralysis 
with metocurine (0.2 mg/kg intravenously). Mechanical 
ventilation of the lung was instituted (ventilator No. 
RSP1002, Kent Scientific Corporation, Litchfield, Conn.) 
with room air with a tidal volume of 12 ml/kg and a rate of 
20 breaths/min. 
A median sternotomy and thymectomy were then done. 
The superior and inferior venae cavae were loosely encir- 
cled with ligatures and the pericardium opened. Both the 
pulmonary artery and aorta were dissected free and 
similarly encircled. A purse-string suture was then placed 
in the free wall of the right ventricle and the rabbit was 
heparinized (500 U/kg intravenously). After injection of 
30 /xg of prostaglandin E~ (PGEI: Alprostadil, Upjohn 
Company, Kalamazoo, Mich.) directly into the pulmonary 
artery, the venae cavae were ligated, thus initiating the 
18-hour ischemic period. 
The pulmonary artery was then cannulated through a 
right ventriculotomy in the center of the purse-string and 
both the right ventricle and pulmonary artery ligatures 
were tied around the cannula. After the left ventricle was 
vented through a left ventriculotomy and the aorta li- 
gated, 50 ml/kg of the preservation solution to be evalu- 
ated as per the protocol was infused into the pulmonary 
artery from a height of 30 cm and at 4 ° C. Topical cooling 
was achieved with cold saline slush. During the pulmonary 
artery flush, the left atrium was cannulated through the 
left ventriculotomy and a second purse-string suture tied 
around the cannula. A second catheter was placed in the 
left atrium to directly transduce l ft atrial pressures. After 
the pulmonary artery flush, the inflow and outflow cannu- 
las were clamped. Care was taken to leave the pleurae 
intact until the completion of the flush to avoid parenchy- 
mal injury. The lungs were stored inflated by clamping the 
tracheal tube at end inspiration. The lung-heart block was 
then excised, immersed in cold 0.9% saline solution, and 
stored at 4 ° C for 18 hours. 
All experimental protocols were reviewed and approved 
by an institutional animal use committee. All animals 
received humane care in compliance with the "Principles 
of Laboratory Animal Care" formulated by the National 
Society for Medical Research and the "Guide for the Care 
and Use of Laboratory Animals" published by the Na- 
tional Institutes of Health (NIH publication No. 86-23, 
revised 1985). 
Assessment of lung function. After 18 hours of storage 
at 4°C the lung-heart block was suspended by a force 
transducer in a warm, humidified tissue chamber. Venti- 
lation was reestablished with a 95% oxygen/5% carbon 
dioxide gas mixture at a tidal volume of 12 ml/kg and a 
respiratory ate of 20 breaths/rain. The lungs were reper- 
fused with homologous fresh whole venous blood from a 
main reservoir. A second venous blood reservoir was used 
to determine single-pass oxygenation at 10, 20, and 30 
minutes after initiation of reperfusion. Blood was har- 
vested from a single rabbit for each experiment. The 
inflow and outflow cannulas were then connected to the 
blood-primed perfusion circuit with care taken to avoid 
the introduction of air. The perfusion circuit (Kent Scien- 
tific Corporation) was designed to recirculate 150 ml of 
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Fig. 1. Schematic diagram of experimental model. 
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warmed blood through a 270 tzm blood filter (No. 2C7600, 
Baxter, Deerfield, Ill.) with a roller pump (No. 7521-40, 
Cole Palmer Instrument Company, Chicago, Ill.) at a rate 
of 60 ml/min (Fig. 1). A 270/xm blood filter was chosen so 
as not to affect leukocyte or platelet counts. 
Continuous recording of pulmonary artery pressure 
(PAP), left atrial pressure, lung weight, airway flow, and 
airway pressure was facilitated by use of a dynamic data 
acquisition program (Workbench PC, Strawberry Tree, 
Inc., Sunnydale, Calif.) run on a PC computer (No. 470A, 
Compaq Prolinea, Houston, Tex.). This program auto- 
matically calculated and displayed pulmonary vascular 
resistance (PVR), tidal volume, and dynamic airway com- 
pliance. The left atrial pressure was maintained within the 
physiologic range (4 to 8 mm Hg) by adjusting the height 
of a small outflow reservoir in the circuit. Pulmonary 
venous blood samples were collected for blood gas anal- 
ysis (Corning 178 pH/blood gas analyzer, Medfield, Mass.) 
at 10, 20, and 30 minutes after the start of reperfusion. At 
each sampling interval inflow from the main reservoir was 
interrupted and the circuit was filled with venous blood 
from the second inflow reservoir. Thirty milliliters of 
venous blood was passed through the pulmonary vascula- 
ture at each interval to ensure accurate measurement of
pulmonary venous oxygen content. Oxygen contact with 
exposed blood surfaces inside the reservoir containers was 
minimized by the continuous infusion of 100% nitrogen. 
After 30 minutes of reperfusion, specimens of lung tissue 
were acquired for weight analysis. Wet-to-dry ratios were 
calculated after passive desiccation at room temperature 
to a stable dry weight. 
Experimental protocol. All lungs were stored inflated at 
4°C for 18 hours after injection of 30 /xg PGE1 and 
single-flush preservation with 50 ml/kg of solution. Three 
experimental groups were defined on the basis of the pres- 
ervation solution the lungs were randomized to receive 
(Table I). The first group of animals (EC group) received 
Euro-Collins olution (N = 8). The second group received 
low-potassium dextran (LPD) solution (N = 8). The third 
group received a flush solution composed of low-potassium 
Table I. Exper imental  protocol  and 
f lush composit ions 
Euro-Collins LPD BLPD 
Component (n = 8) (n - 8) (n = 7) 
Na + (mmol/L) 10 71.5 98.5 
K + (mmol/L) 115 2.2 3.3 
CI (mmol/L) 15 60 80 
HCO 3 (mmol/L) 10 - -  - -  
HPO4 2 (mmol/L) 42.5 14 i4 
H2PO 4 (mmol/L) 15 - -  - -  
Mg 2+ (mmol/L) - -  2.0 2.0 
Ca 2+ (mg/dl) - -  1.5 3.5 
Lactate (retool/L) - -  15.4 15.4 
Dextran (grn/L) - -  25 25 
Dextrose (gin/L) 35 15 15 
Donor blood (%) - -  - -  20 
pH (4 ° C) 7.25 7.3-7.5 7.3-7.5 
dextran solution with a 20% addition of autologous hepa- 
rinized whole venous blood (BLPD solution) (N = 7). All 
lungs were reperfused at a physiologic flow rate of 60 ml/min 
for 30 minutes. Data were recorded every 15 seconds and 
analyzed at the end of the 30-minute reperfusion period. 
Oxygenation data were obtained and analyzed at 10-minute 
intervals. All values are expressed as the mean plus or minus 
the standard error of the mean. Statistical nalysis was done 
by analysis of variance to compare the experimental groups. 
Differences were considered statistically significant if the p 
value was less than 0.05. 
Results 
Pulmonary function was assessed uring reperfu- 
sion by the following parameters:  PAP,  PVR, dy- 
namic lung compliance, and oxygenation capacity. 
In our model,  we defined oxygenation capacity as 
the ability of the lungs to oxygenate venous b lood 
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Table II. Parameters of lung function after 30 minutes of reperfusion 
PAP PVR CPL Wet~dry V-A Oe 
Group (ram Hg) (dynes'sec.cm - 5 ) (%A) ratio (ram Hg) 
EC (n = 8) 40.8 _+ 2.2* 46.0 _+ 3.1~ -21 .9  _+ 4.7~ 7.4 _+ 0.3§ 37.2 _+ 4.611 
LPD (n = 8) 28.9 _+ 2.4 29.0 _+ 4.2 1.8 _+ 3.3 5.6 + 0.1 296.3 _+ 54.6 
BLPD (n = 7) 28.3 _+ 1.5 28.8 _+ 2.3 1.4 _+ 6.2 5.7 _+ 0.3 290.2 _+ 66.4 
Values demonstrate superior preservation with extracellular solutions (LPD and BLPD) as compared with preservation with Euro-Collins olution. V-A 0:~ 
venous-arterial oxygen gradient. 
*p = 0.0003 versus LPD and BLPD groups. 
-J'p = 0.0005 versus LPD and BLPD groups. 
Sp = 0.002 versus LPD and BLPD groups. 
§p = 0.0001 versus LPD and BLPD groups. 
I[o = 0.001 versus LPD and BLPD groups. 
during a single pass from the pulmonary artery to 
the left atrium. It is reported as a venous-arterial 
gradient o normalize for gradual decreases that 
occur in the venous blood oxygen tension during the 
course of the experiment. At the end of the 30- 
minute reperfusion period tissue samples were ob- 
tained for determination f wet-to-dry ratios. 
Lungs preserved with LPD and BLPD solutions 
demonstrated improvement in all parameters of 
pulmonary function when compared with results in 
the EC group after 30 minutes of reperfusion (Table 
II). The EC group demonstrated a significant eleva- 
tion in PAP when compared with values in the LPD 
and BLPD groups (40.8 _+ 2.2 mm Hg vs 28.9 _+ 2.4 
mm Hg and 28.3 _+ 1.5 mm Hg, respectively; p < 
0.001). Similarly, PVR was elevated (46.0 + 3.1 × 
103 dynes.sec.cm -5 vs 29.0 + 4.2 × 103 
dynes.sec-cm -5 and 28.8 _+ 2.3 × 103 
dynes, sec-cm -5, respectively; p < 0.001). These 
values are elevated because of the perfusion circuit; 
however, absolute differences between groups are 
caused by changes in the pulmonary vasculature as a 
result of preservation. The EC group revealed a 
greater drop in compliance when compared with the 
LPD and BLPD groups (-21.9% _+ 4.7% vs 1.8% + 
3.3% and 1.4% + 6.2%, respectively; p = 0.002). 
Oxygenation capacity in both groups that received 
extracellular-type solutions (LPD and BLPD 
groups) was significantly improved as compared 
with that in the EC group (296.3 _+ 54.6 mm Hg and 
290.2 + 66.4 mm Hg, respectively, vs37.2 _+ 4.6 mm 
Hg; p = 0.001) (Fig. 2). In addition, LPD- and 
BLPD-preserved lungs had less edema formation at 
the end of the reperfusion period when compared 
with that in the EC group (wet-to-dry ratios: 5.6 + 
0.1 and 5.7 _+ 0.3, respectively, vs 7.4 _+ 0.3; p = 
0.0001). 
When the LPD group was compared with the 
BLPD group, no significant differences in pulmo- 
nary function were demonstrated in any of the 
parameters measured. 
Discussion 
Despite recent advances in virtually all aspects of 
lung transplantation, reliable extended graft preser- 
vation has not been achieved. Even with limited 
storage periods of less than 6 hours, varying degrees 
of reperfusion injury are encountered frequently 
and at times even result in graft failure. This injury 
is often attributable to, or exacerbated by, inade- 
quate graft preservation. Single-flush perfusion of 
the pulmonary vasculature is a widely accepted 
method of lung preservation because of its simple 
application, lack of cardiac effects, and acceptable 
results. However, variable results have been re- 
ported depending on the type of preservation solu- 
tion used with this technique. 6-1s 
Previously, we have demonstrated that a low- 
potassium solution improves lung function whereas 
Euro-Collins olution exacerbates lung injury in the 
setting of high-flow reperfusion. 19' 20 These studies 
were not designed to specifically evaluate the pres- 
ervation characteristics of these solutions and were 
therefore done after a relatively short storage period 
of 4 hours to minimize the effects of ischemia. In the 
current study we used an isolated, ventilated/blood- 
perfused rabbit lung model to directly compare 
three lung preservation solutions and determine 
whether extracellular solutions provide superior 
protection of the lung after 18 hours of cold isch- 
emia. Euro-Collins olution was chosen as a repre- 
sentative intracellular solution inasmuch as it is 
commonly used in clinical practice. 
In this experiment, lungs preserved with extracel- 
lular-type solutions, LPD and BLPD, demonstrated 
improved function as compared with function in 
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lungs preserved with Euro-Collins solution. This 
improvement was seen in all parameters of lung 
function; most dramatically in the lung's ability to 
oxygenate venous blood. Oxygenation during reper- 
fusion remains the single most important indicator 
of adequate pulmonary preservation, and these dif- 
ferences between extracellular nd intracellular so- 
lutions suggest both harmful effects of Euro-Collins 
solution and beneficial effects of LPD and BLPD 
solutions. 
Euro-Collins olution is an intracellular-type so- 
lution initially designed to protect renal parenchy- 
mal cells from inappropriate cation exchange and 
cell edema during ischemia. 21 However, the lung is 
physiologically and anatomically distinct from the 
kidney, therefore renal preservation strategies may 
not be optimal for a pulmonary graft. The lung is 
unique in its ability to maintain aerobic metabolism 
during ischemia s it uses oxygen stored within the 
alveoli.22, 3 Therefore the lung is relatively tolerant 
of ischemia. Euro-Collins olution, which stabilizes 
cation flux and prevents cellular edema during the 
ischemic interval, is poorly designed to protect an 
organ whose morphologic structure minimizes the 
effects of ischemia, provided it is stored in the 
inflated state. By clamping the trachea t end inspi- 
ration before storage, oxygen is maintained in the 
alveolar space to allow for ongoing metabolism. 
In addition, the high potassium content of Euro- 
Collins solution, included to minimize cation flux 
and preserve nergy stores, has profound effects on 
the pulmonary vasculature. Potassium-induced va-
soconstriction not only causes increased PVR dur- 
ing early reperfusion but also results in nonhomo- 
geneous flushing of the graft and poorly preserved 
areas of parenchyma.ll' 20, 24, 25 High potassium con- 
tents also have a direct effect on endothelial cell 
function 26 and have been shown to be injurious to 
type II pneumocytes in cell culture. 27 Our findings in 
this study corroborate the detrimental effects of 
potassium on the pulmonary vasculature. The EC 
group had significant elevations in PAP and PVR 
even after 30 minutes of reperfusion, which suggests 
endothelial cell dysfunction or injury. PGE 1 has 
been used to overcome the potassium-induced va-
soconstriction caused by intracellular-type solutions 
and may also provide additional preservation bene- 
fits. Whether PGE 1 is effective in overcoming this 
vasoconstriction a d improving pulmonary function 
is controversial. 13'24 Several investigators have di- 
rectly compared low-potassium extracellular-type 
solutions with intracellular-type solutions 11' 28, 2s; 
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Fig. 2. Pulmonary venous-arterial oxygen gradient at 10, 
20, and 30 minutes of reperfusion. Both LPD and BLPD 
solutions demonstrated significant improvement i  oxy- 
genation over that in lungs preserved with Euro-Collins 
solution. Pao z Arterial oxygen tension. 
however, these studies did not use PGE 1 before 
flushing of the graft. In this study we have demon- 
strated that lung function after preservation with 
Euro-Collins solution is inferior to that with both 
LPD and BLPD solution, despite the use of PGE 1. 
A potential limitation of this model may be the 
inherent sensitivity of the vasculature ofRodentia to 
high concentrations of potassium, resulting in a 
more severe injury. However, the human pulmonary 
vasculature also remains ensitive to potassium at 
comparable concentrations 29 and may be subject o 
these detrimental effects. 
The beneficial effects of the extracellular-type 
solutions investigated (LPD and BLPD) may not 
only be a result of the low potassium contents, but 
also of the addition of dextran. Belzer and 
Southard 2sdescribed impermeants a  key compo- 
nents of successful cold storage solutions. In the 
lung, where interstitial edema impairs its most im- 
portant function of gas exchange, the role of imper- 
meants may be even more significant. Additional 
benefits of dextran may be a result of enhanced flow 
characteristics in the capillaries, antithrombotic 
properties via effects on the endothelium and plate- 
lets, and its potential free-radical scavenging abili- 
ties. 3° Significantly improved wet-to-dry ratios were 
seen with the use of dextran in our model, which 
supports the importance of including an imper- 
meant in lung preservation solutions. 
In this model of 18-hour ischemia we were unable 
to demonstrate any advantage with the addition of 
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whole heparinized blood to the preservation solu- 
tion. The theoretic benefits of including blood in 
organ preservation solutions include provision of 
substrates for continued metabolism and intact buff- 
ering mechanisms. 16 The inclusion of blood also 
provides additional impermeants. We were unable 
to reveal any significant differences between the 
LPD and BLPD solutions in this model. Perhaps a 
longer period of ischemia would have elucidated any 
advantages that blood may confer in pulmonary 
preservation solutions. The detrimental effects of 
leukocytes on lung function after preservation have 
been demonstrated, 1-4 and perhaps the addition of 
leukocyte-free blood would be more appropriate. 
In conclusion, lung preservation with extracellu- 
lar-type solutions, LPD and BLPD, resulted in 
superior pulmonary function as compared with the 
use of Euro-Collins solution in this rabbit lung 
model. We believe the ideal solution for lung pres- 
ervation will place less emphasis on parenchymal 
preservation and focus instead on protecting the 
endothelium from the detrimental events that occur 
during reperfusion. Improved preservation will 
likely result in a decreased prevalence and severity 
of reperfusion i jury after lung transplantation. 
We acknowledge the technical advice of Anthony J. 
Herring. 
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Discuss ion  
Dr. Larry R. Kaiser (Philadelphia, Pa.). Could some of 
the advantage from the blood-based solution possibly be 
due to a variation in the distribution? Perhaps the in- 
creased viscosity of the blood-based solution might con- 
tribute to a poorer distribution. Is there any way to look at 
that? 
Dr. Binns. We did not investigate that in any way. 
Methods have been reported in which one could use 
labeled albumin or some other technique to track where 
the perfusate isgoing throughout the lung, but we did not 
look at that at all. 
Dr. G. Alexander Patterson (St. Louis, Mo.). We pub- 
lished some work quite a while ago that said LPD solution 
was a superior preservation solution in a variety of 
models, and then it happened that we determined in a 
group of canine experiments and a group of canine 
reports that so long as the donor lung was vasodilated or 
pretreated by PGE1, prostacyclin, high-volume ventila- 
tion, or any method that achieved satisfactory vasodilata- 
tion, that any difference in LPD solution was eliminated. 
This study was conducted in rabbits, correct? I think it is 
impossible to get Euro-Collins olution or an intracellular 
solution into a rabbit or rodent lung, whereas it is easy to 
flush them with an extracellular solution. I would appre- 
ciate your comments on how much of these results you 
think are species dependent. 
Dr. Binns. We have to be cautious any time we extrap- 
olate our results in small animal studies to the human 
situation, or even to larger animal studies for that matter. 
The pulmonary vasculature of the rabbit is definitely 
responsive to potassium; however, the human vasculature 
also remains responsive to potassium at even low concen- 
trations of 20 mmol/L. I think that some of the responses 
we see are definitely occurring in the human vasculature. 
We may not be able to demonstrate he response quite as 
dramatically because of the larger capacitance vascular 
bed that we are perfusing. In any case, we have to be 
cautious when applying these findings in experimental 
models to human situations. A randomized, prospective 
clinical study is needed to clarify this issue. 
Dr. Shaf Keshavjee (Toronto, Ontario, Canada). Along 
the same lines, I think that the improvement in lung 
preservation related to LPD versus Euro-Collins olution 
in this setting was much greater. Even though the buffer- 
ing effect of blood has been shown to be beneficial, it is a 
smaller effect, and I wonder whether with 50 ml/kg of flush 
solution there was still blood in the lungs and therefore 
there was a buffering effect of blood even in the LPD 
group compared with the blood plus LPD group? 
Dr. Binns. The only comment I can make is that the 
effluent from the venous outflow cannulas after flushing 
the lungs was clear, but we did not actually measure the 
hematocrit value. 
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